Clinical Trial Detail

NCT ID NCT02078648
Title Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Stemline Therapeutics, Inc.
Indications

oligodendroglioma

gliosarcoma

giant cell glioblastoma

Therapies

SL-701

Poly ICLC

Bevacizumab

Age Groups: adult

No variant requirements are available.